1. Home
  2. MTVA vs ABVE Comparison

MTVA vs ABVE Comparison

Compare MTVA & ABVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTVA
  • ABVE
  • Stock Information
  • Founded
  • MTVA 2014
  • ABVE 2019
  • Country
  • MTVA United States
  • ABVE Canada
  • Employees
  • MTVA N/A
  • ABVE N/A
  • Industry
  • MTVA
  • ABVE Packaged Foods
  • Sector
  • MTVA
  • ABVE Consumer Staples
  • Exchange
  • MTVA NYSE
  • ABVE Nasdaq
  • Market Cap
  • MTVA 12.5M
  • ABVE 9.7M
  • IPO Year
  • MTVA N/A
  • ABVE N/A
  • Fundamental
  • Price
  • MTVA $1.48
  • ABVE $0.36
  • Analyst Decision
  • MTVA Strong Buy
  • ABVE
  • Analyst Count
  • MTVA 1
  • ABVE 0
  • Target Price
  • MTVA $12.00
  • ABVE N/A
  • AVG Volume (30 Days)
  • MTVA 25.3K
  • ABVE 233.1K
  • Earning Date
  • MTVA 03-27-2025
  • ABVE 02-15-2025
  • Dividend Yield
  • MTVA N/A
  • ABVE N/A
  • EPS Growth
  • MTVA N/A
  • ABVE N/A
  • EPS
  • MTVA N/A
  • ABVE N/A
  • Revenue
  • MTVA N/A
  • ABVE $275,376,450.00
  • Revenue This Year
  • MTVA N/A
  • ABVE N/A
  • Revenue Next Year
  • MTVA N/A
  • ABVE N/A
  • P/E Ratio
  • MTVA N/A
  • ABVE N/A
  • Revenue Growth
  • MTVA N/A
  • ABVE N/A
  • 52 Week Low
  • MTVA $1.29
  • ABVE $0.25
  • 52 Week High
  • MTVA $5.53
  • ABVE $4.07
  • Technical
  • Relative Strength Index (RSI)
  • MTVA N/A
  • ABVE N/A
  • Support Level
  • MTVA N/A
  • ABVE N/A
  • Resistance Level
  • MTVA N/A
  • ABVE N/A
  • Average True Range (ATR)
  • MTVA 0.00
  • ABVE 0.00
  • MACD
  • MTVA 0.00
  • ABVE 0.00
  • Stochastic Oscillator
  • MTVA 0.00
  • ABVE 0.00

About MTVA METAVIA INC

MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

About ABVE Above Food Ingredients Inc. Common Stock

Above Food Ingredients Inc is a differentiated, regenerative ingredient company. Its products are made with real nutritious, flavorful ingredients and delivered with transparency. Its vision is to create a healthier world one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence driven genomics. The company delivers nutritious foods to businesses and consumers with traceability and sustainability. Above Food's consumer products and brands are available in grocers across Canada and the United States.

Share on Social Networks: